Protalix BioTherapeutics For Profit
Protalix is dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles, produced with its ProCellEx® plant cell-based expression system
Investors
Founded Date:
1994-01-01
Last Funding Type:
Seed
Headquarters:
Carmiel, HaZafon, Israel
Investors Number:
1
Technology:
Drug development
Employee Number:
501-1000
Industry:
PharmTech
Estimated Revenue:
$10M to $50M
Funding Status:
IPO
Total Funding:
$10.8M